WASHINGTON, D.C. (Feb. 19, 2026) — A new poll suggests that Republican voter enthusiasm for the November midterm elections could decline if the Trump administration does not take stronger action on abortion policy — particularly regarding the abortion pill mifepristone.
The survey of 1,000 Republican primary voters nationwide was conducted by Cygnal and commissioned by Susan B. Anthony Pro-Life America. It carries a margin of error of ±4.76%.
Base Concern Over Mifepristone Policy
According to the findings, 70.8% of Republican primary voters oppose continuing the Biden-era policy allowing mifepristone to be dispensed through the mail and prescribed via telehealth without an in-person visit. Only 18.8% support maintaining the current rules, while 10.4% remain unsure.
Additionally:
- 73.5% said mail delivery of mifepristone undermines pro-life laws in certain states.
- 77.5% support reinstating an in-person doctor’s visit requirement before prescribing the drug.
- Nearly 80% favor maintaining a ban on federal taxpayer funding for abortion.
The policy changes in question were implemented under former President Joe Biden in 2023, removing in-person dispensing requirements.
Midterm Enthusiasm at Stake
The poll also measured potential electoral impact.
- 31.7% of respondents said their enthusiasm to vote Republican in November would decrease if the party weakens or abandons pro-life priorities.
- Nearly 34% said they would be less likely to volunteer or campaign for Republican candidates under those circumstances.
- 43% said their enthusiasm would remain unchanged, while 13.6% said it would increase.
Marjorie Dannenfelser, president of SBA Pro-Life America, warned during a virtual press conference that failing to address abortion drug regulations could create “an electoral problem in addition to a moral problem.”
“We have been warning the party and the administration for months,” she said. “The failure to rein in abortion drugs risks base enthusiasm this November.”
Federal Review Ongoing
In May 2025, Robert F. Kennedy Jr., Secretary of the Department of Health and Human Services, announced a review of the regulatory changes. The Food and Drug Administration began its review in September 2025.
As of February 2026, no regulatory changes have been announced. The FDA has stated that the review is ongoing and aims to be completed “as soon as possible,” noting such studies can take a year or more.
Critics argue the delay reflects political caution. HHS has denied allegations that the process is being slowed for political reasons.
Political Balancing Act
For President Donald Trump, the issue highlights a broader challenge: balancing appeals to a national electorate with maintaining enthusiasm among a socially conservative base.
With the midterm elections approaching, the administration’s handling of abortion policy — especially medication abortion — may test Republican unity and voter mobilization efforts in key races across the country.
Whether regulatory action is taken in the coming months could play a role in shaping turnout dynamics and grassroots engagement heading into November.